Related News
Home » Business » Manufacturing
Vertex set to sell milestone rights on hepatitis drug
Source: Agencies |
July 11, 2009, Saturday
|
Print Edition
Print Edition
VERTEX Pharmaceuticals Inc said yesterday it planned to sell rights to future milestone payments tied to progress in Europe for its high-profile experimental hepatitis C drug.
The payments would come from Johnson & Johnson, which licensed European rights to the drug, telaprevir, from Vertex three years ago. Vertex retains rights to the drug in North America.
The milestones anticipated for telaprevir in Europe include US$100 million related to regulatory filing and approval for telaprevir and US$150 million related to its launch.
Telaprevir is being observed in three studies with more than 2,200 patients in the United States and Europe.
The payments would come from Johnson & Johnson, which licensed European rights to the drug, telaprevir, from Vertex three years ago. Vertex retains rights to the drug in North America.
The milestones anticipated for telaprevir in Europe include US$100 million related to regulatory filing and approval for telaprevir and US$150 million related to its launch.
Telaprevir is being observed in three studies with more than 2,200 patients in the United States and Europe.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
